The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALNY | +56.81% | +252.62% | +28.67% | +7,635% |
| S&P | +14.5% | +93.32% | +14.09% | +498% |
Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Here are the five best biotech ETFs to invest in right now.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $773.69M | 17.3% |
| Gross Profit | $630.74M | 6.7% |
| Gross Margin | 81.52% | -8.1% |
| Market Cap | $42.52B | 38.3% |
| Market Cap / Employee | $19.07M | 0.0% |
| Employees | 2.2K | 6.2% |
| Net Income | -$66.28M | -292.4% |
| EBITDA | -$2.26M | -103.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.11B | 15.0% |
| Accounts Receivable | $567.11M | 83.2% |
| Inventory | 71.7 | -14.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.60B | -0.3% |
| Short Term Debt | $143.62M | 38.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -7.44% | -5.5% |
| Return On Invested Capital | -28.39% | 8.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $139.44M | 20.1% |
| Operating Free Cash Flow | $153.73M | 23.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -11478.71 | 937.04 | 520.39 | 368.11 | -362.66% |
| Price to Sales | 16.88 | 13.51 | 14.91 | 17.30 | 31.71% |
| Price to Tangible Book Value | -11480.15 | 937.06 | 520.39 | 368.11 | -362.66% |
| Price to Free Cash Flow TTM | 573.22 | 147.48 | 96.58 | 2201.71 | - |
| Enterprise Value to EBITDA | -561.19 | -334.44 | 1080.76 | -18837.53 | -3980.82% |
| Free Cash Flow Yield | 0.2% | 0.7% | 1.0% | 0.0% | - |
| Return on Equity | -257.8% | - | |||
| Total Debt | $2.73B | $2.74B | $2.72B | $2.74B | 1.16% |
ALNY earnings call for the period ending September 30, 2021.
ALNY earnings call for the period ending June 30, 2021.
ALNY earnings call for the period ending March 31, 2021.
ALNY earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
